ArrhythmiaWATCHinTIMENCT06482320
Diagnostic Accuracy in the Detection of Arrhythmias of Patient Recorded ECGs With Smart WATCH TIMEly Performed During Palpitations
An observational study of Arrhythmia, run by University Hospital of Ferrara at 1 site in Italy.
Trial summary
Approximately 100 patients with heart palpitations over the age of 22, in possession of smartwatches capable of recording a single-lead ECG will be enrolled. The study plans to evaluate the performance in the diagnosis of arrhythmia of single-lead ECGs self-recorded by patients during heart palpitations using a… Read more about this study
- Who is it for?
- Ages 22 to 100 years
- Conditions the study is for
- Arrhythmia
- What is being tested?
- Recording EKG traces on the smartwatch
- How many people
- 100 participants
- Where
- 1 siteItaly
- Study dates
- 1 Feb 2024to 1 Oct 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients aged 22 years or over referring to the outpatient clinics of the participating centers for heart palpitations, owners of Smart Watches capable of recording ECGs.
Who may be able to join
- Patients attending the outpatient clinics of the participating heart palpitations owners of smartwatches and mobile phones capable of recording a single-lead ECG on request
- Patients 22 years of age and older
- Patients able to send recorded traces in PDF format by e-mail.
- Signature of consent
Who cannot join
- Under 22 years of age
- Carriers of ICDs, S-ICDs, pacemakers, loop recorders.
- Known left bundle branch block although frequency dependent on a previous baseline ECG or Holter ECG
- Known right bundle branch block with QRS duration greater than or equal to 120 ms even if frequency dependent on a previous baseline ECG or Holter ECG
- State of pregnancy;
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
Azienda Ospedaliero-Universitaria di Ferrara
Ferrara, 44124
Matteo Bertini, MD, PhD, 0532236269, brtmtt2@unife.it
About this study
Approximately 100 patients with heart palpitations over the age of 22, in possession of smartwatches capable of recording a single-lead ECG will be enrolled.
The study plans to evaluate the performance in the diagnosis of arrhythmia of single-lead ECGs self-recorded by patients during heart palpitations using a smartwatch.
Read the detailed description
The patient who complains of palpitations can undergo multiple evaluations in the absence of a definitive diagnosis, especially in the case of paroxysmal arrhythmias of short duration. There are methods that allow prolonged cardiac rhythm recordings but which in clinical practice are not always available even in the face of high costs. Smartwatches capable of recording single-lead ECGs are increasingly popular even among patients who come to health services complaining of heart palpitations. The traces recorded can be diagnostic for atrial fibrillation but cases suggesting other types of arrhythmias are also reported, later confirmed by further investigations.
Therefore, the patient with heart palpitations who already owns a Smart Watch capable of recording ECGs can, if adequately involved, contribute in an innovative and economic way to the diagnosis of arrhythmia.
The rationale of this study is to evaluate the performance in the diagnosis of arrhythmia of the ECGs sent via smartwatch by patients in case of heart palpitations.
This is an observational, prospective, non-randomized multicenter study that involves the collection of clinical and electrocardiographic data of patients (over the age of 22) referring to the outpatient clinics of the participating centers for heart palpitations, owners of Smart Watches capable of recording ECGs.
Before enrollment, the Smart Watch will be identified by checking whether it belongs to the list of devices capable of recording single-lead ECG Upon enrollment, enrolled patients are associated with an identification number with progressive numbering (ID). They will then be instructed to record a basal mono-lead ECG (ECG 0) using their smart watch and will be invited to send the recorded file to a separate and specific e-mail address dedicated to the study for each participating centre. The sender's e-mail address will be recorded and associated with the ID of the enrolled patient, becoming the only element capable of providing an association between traces sent in the future and the belonging ID. The main clinical and personal data including the telephone number will also be collected.
Following enrollment, a 24-hour Holter ECG will be performed at the outpatient clinic of the enrolling center.
From the date of enrollment and for the following three months, before after and during the execution of the 24-hour Holter ECG, enrolled patients can send the single-lead ECGs recorded with their own device to the e-mail address prepared and specific for each participating centre. The ECGs sent will be evaluated electively (in the days following the sending of the patient's e-mail) by the enrolling doctors of the interested participating center. On the basis of the clinical significance of the mono-lead ECGs, the doctors themselves will take care of communicating to the patient via e-mail indications relating to the continuation of the follow-up (e.g.: invitation to send further tracings, absence of further measures in case of ECG single-lead non-pathological). In the event of diagnostic and/or therapeutic measures to be implemented following the reading of a trace sent (e.g. specialist visit in the outpatient clinics of the Participating Center), the doctor will contact the patient on the telephone number provided during enrollment for taking in charge.
- Conditions
- Arrhythmia
- Being tested
- Recording EKG traces on the smartwatch
- Keywords
- smartwatch, Arrhythmia, palpitation
- Medical subject headings
- Arrhythmias, Cardiac
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Recording EKG traces on the smartwatchDiagnostic test
Upon enrollment, patients are associated with a progressive identification number (ID). They will then be instructed to record a baseline single-lead EKG (EKG 0) to be sent to a dedicated email address. The sender's email address will be recorded and associated with the ID. The main clinical and demographic data will also be collected. Within 30 days of the enlistment date, a 24-hour EKG Holter will be performed. From the date of enlistment and for the following three months, before, after and during the execution of the 24-hour EKG Holter, enrolled patients can send single-lead EKGs (recorder throug the smartwatch) in case of palpitation. The report of the single-lead EKGs will be communicated electively via e-mail (in response to the email sent by the patient and containing the trace in question) in the following days. In case of diagnostic and/or therapeutic measures to be implemented following the reporting of the trace, doctors will take care of it.
| Study group | Role | What they receive |
|---|---|---|
| Study Group | Adults aged between 22 and 70 years and owners of smartwatch capable of EKG recording referred at the ER, Cardiology ward or Cardiology Clinic for palpitation are eligible according to the inclusion criteria. Receives: Diagnostic Test: Recording EKG traces on the smartwatch |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compare the accuracy of physician rhythm interpretation vs interpretation of 1-lead ECG generated provided by the Watch.
Compare the accuracy of physician rhythm interpretation vs interpretation of 1-lead ECG generated provided by the Watch
Measured: 3 month after the enrollment
Assessment of diagnostic accuracy of 1-lead ECGs interpretation for different cardiac arrhythmias (compared to standard ecg or h24-h holter)
Assessment of diagnostic accuracy of 1-lead ECGs interpretation for different cardiac arrhythmias (compared to standard ecg or h24-h holter)
Measured: 3 month after the enrollment
Secondary outcomes (2)
Compare the accuracy of automatic AF detection of the Watch versus a cardiologist interpretation of a 12-lead ECG (gold-standard)
Compare the accuracy of automatic AF detection of the Watch versus a cardiologist interpretation of a 12-lead ECG (gold-standard)
Measured: 3 month after the enrollment
evel of agreement of measured interval duration between the Watch 1-lead ECG and a 12-lead ECG.
evel of agreement of measured interval duration between the Watch 1-lead ECG and a 12-lead ECG.
Measured: 3 month after the enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2024
- Study start1 Feb 2024
- Primary completion1 Apr 2025 (estimated)
- Study completion1 Oct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ArrhythmiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital of Ferrara
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Matteo Bertini, MD, Principal investigator, Ferrara University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06482320
- Sponsor's protocol ID
- 111/2023/Oss/AOUFe
- Acronym
- WATCHinTIME
- Status last verified
- Jan 2024
- First submitted
- 25 Jun 2024
- Last updated
- 1 Jul 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diagnostic Accuracy in the Detection of Arrhythmias of Patient Recorded ECGs With Smart WATCH TIMEly Performed During Palpitations
- ClinicalTrials.gov ID
- NCT06482320
- Acronym / sponsor ID
- WATCHinTIME / 111/2023/Oss/AOUFe
- Conditions
- Arrhythmia
- Keywords
- smartwatch, Arrhythmia, palpitation
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University Hospital of FerraraUniversity, hospital or other
- Study start
- 1 Feb 2024 (actual)
- Primary completion
- 1 Apr 2025 (estimated)
- Study completion
- 1 Oct 2025 (estimated)
- First posted
- 1 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Approximately 100 patients with heart palpitations over the age of 22, in possession of smartwatches capable of recording a single-lead ECG will be enrolled.
The study plans to evaluate the performance in the diagnosis of arrhythmia of single-lead ECGs self-recorded by patients during heart palpitations using a smartwatch.
Detailed description
The patient who complains of palpitations can undergo multiple evaluations in the absence of a definitive diagnosis, especially in the case of paroxysmal arrhythmias of short duration. There are methods that allow prolonged cardiac rhythm recordings but which in clinical practice are not always available even in the face of high costs. Smartwatches capable of recording single-lead ECGs are increasingly popular even among patients who come to health services complaining of heart palpitations. The traces recorded can be diagnostic for atrial fibrillation but cases suggesting other types of arrhythmias are also reported, later confirmed by further investigations.
Therefore, the patient with heart palpitations who already owns a Smart Watch capable of recording ECGs can, if adequately involved, contribute in an innovative and economic way to the diagnosis of arrhythmia.
The rationale of this study is to evaluate the performance in the diagnosis of arrhythmia of the ECGs sent via smartwatch by patients in case of heart palpitations.
This is an observational, prospective, non-randomized multicenter study that involves the collection of clinical and electrocardiographic data of patients (over the age of 22) referring to the outpatient clinics of the participating centers for heart palpitations, owners of Smart Watches capable of recording ECGs.
Before enrollment, the Smart Watch will be identified by checking whether it belongs to the list of devices capable of recording single-lead ECG Upon enrollment, enrolled patients are associated with an identification number with progressive numbering (ID). They will then be instructed to record a basal mono-lead ECG (ECG 0) using their smart watch and will be invited to send the recorded file to a separate and specific e-mail address dedicated to the study for each participating centre. The sender's e-mail address will be recorded and associated with the ID of the enrolled patient, becoming the only element capable of providing an association between traces sent in the future and the belonging ID. The main clinical and personal data including the telephone number will also be collected.
Following enrollment, a 24-hour Holter ECG will be performed at the outpatient clinic of the enrolling center.
From the date of enrollment and for the following three months, before after and during the execution of the 24-hour Holter ECG, enrolled patients can send the single-lead ECGs recorded with their own device to the e-mail address prepared and specific for each participating centre. The ECGs sent will be evaluated electively (in the days following the sending of the patient's e-mail) by the enrolling doctors of the interested participating center. On the basis of the clinical significance of the mono-lead ECGs, the doctors themselves will take care of communicating to the patient via e-mail indications relating to the continuation of the follow-up (e.g.: invitation to send further tracings, absence of further measures in case of ECG single-lead non-pathological). In the event of diagnostic and/or therapeutic measures to be implemented following the reading of a trace sent (e.g. specialist visit in the outpatient clinics of the Participating Center), the doctor will contact the patient on the telephone number provided during enrollment for taking in charge.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Study Group | – | Diagnostic Test: Recording EKG traces on the smartwatchAdults aged between 22 and 70 years and owners of smartwatch capable of EKG recording referred at the ER, Cardiology ward or Cardiology Clinic for palpitation are eligible according to the inclusion criteria. |
Who may qualify
- Ages
- 22 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients aged 22 years or over referring to the outpatient clinics of the participating centers for heart palpitations, owners of Smart Watches capable of recording ECGs.
Key inclusion criteria (4 listed)
- Patients attending the outpatient clinics of the participating heart palpitations owners of smartwatches and mobile phones capable of recording a single-lead ECG on request
- Patients 22 years of age and older
- Patients able to send recorded traces in PDF format by e-mail.
- Signature of consent
Key exclusion criteria (5 listed)
- Under 22 years of age
- Carriers of ICDs, S-ICDs, pacemakers, loop recorders.
- Known left bundle branch block although frequency dependent on a previous baseline ECG or Holter ECG
- Known right bundle branch block with QRS duration greater than or equal to 120 ms even if frequency dependent on a previous baseline ECG or Holter ECG
- State of pregnancy;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Recording EKG traces on the smartwatchUpon enrollment, patients are associated with a progressive identification number (ID). They will then be instructed to record a baseline single-lead EKG (EKG 0) to be sent to a dedicated email address. The sender's email address will be recorded and associated with the ID. The main clinical and demographic data will also be collected. Within 30 days of the enlistment date, a 24-hour EKG Holter will be performed. From the date of enlistment and for the following three months, before, after and during the execution of the 24-hour EKG Holter, enrolled patients can send single-lead EKGs (recorder throug the smartwatch) in case of palpitation. The report of the single-lead EKGs will be communicated electively via e-mail (in response to the email sent by the patient and containing the trace in question) in the following days. In case of diagnostic and/or therapeutic measures to be implemented following the reporting of the trace, doctors will take care of it. | Diagnostic test | Study Group |
Primary outcome
Compare the accuracy of physician rhythm interpretation vs interpretation of 1-lead ECG generated provided by the Watch.
Time frame: 3 month after the enrollment
Compare the accuracy of physician rhythm interpretation vs interpretation of 1-lead ECG generated provided by the Watch
Assessment of diagnostic accuracy of 1-lead ECGs interpretation for different cardiac arrhythmias (compared to standard ecg or h24-h holter)
Time frame: 3 month after the enrollment
Assessment of diagnostic accuracy of 1-lead ECGs interpretation for different cardiac arrhythmias (compared to standard ecg or h24-h holter)
2 secondary outcomes
Compare the accuracy of automatic AF detection of the Watch versus a cardiologist interpretation of a 12-lead ECG (gold-standard)
Time frame: 3 month after the enrollment
evel of agreement of measured interval duration between the Watch 1-lead ECG and a 12-lead ECG.
Time frame: 3 month after the enrollment
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2024.
- Individual participant dataSharing planned: No
Related trials for Arrhythmia
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
Not yet recruiting
nCPAP-NAVA-Backup Versus Standard nCPAP for Severe Apnea in Preterm Infants ≤28 Weeks
Apnea of Prematurity
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Enrolling by invitation
VINTAGE (Ventricular Intramyocardial Navigation for Tachycardia Ablation Guided by Electrograms) Using Commercial Off-The-Shelf (COTS) Catheters
Ventricular Arrhythmia
Enrolling by invitation
EDEN Intracardiac Electrogram Recording and Classifying System
Ventricular Arrhythmia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Matteo Bertini, MD principal investigator
Ferrara University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Arrhythmia, run by University Hospital of Ferrara at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Matteo Bertini, MD (0532236269, doc.matber@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compare the accuracy of physician rhythm interpretation vs interpretation of 1-lead ECG generated provided by the Watch. (time frame: 3 month after the enrollment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2024.